Email this article VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer
- Authors: Pignata S1
-
Affiliations:
- Национальный институт рака IRCCS Фонда Дж.Паскаля, Неаполь, Италия
- Issue: Vol 15, No 2 (2013)
- Pages: 40-44
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26901
- ID: 26901
Cite item
Full Text
Abstract
O affect angiogenesis is one of the key goals of therapy for ovarian cancer (OC). The advent of targeted drugs that selectively affect neoangiogenesis has been a breakthrough in treating OC in the past decade. By now the only drug validly demonstrating antiangiogenic activity is bevacizumab whose efficacy has been tested in Phases II and III trials of OC. Bevacizumab has been approved by the European Medicines Agency for use in the first-line therapy of OC and in combination with standard chemotherapy to treat platinum-sensitive recurrent OC. This paper gives the results obtained from further clinical trials of bevacizumab, which expand the spectrum of indications of this targeted angiogenesis inhibitor for the treatment of the disease.
Full Text
##article.viewOnOriginalSite##References
- Статистические данные доступны на сайте Globocan по ссылке: http://globocan.iarc.fr/summary_table_pop.asp от 05.02.2013
- Han E.S et al. Treatment of Ovarian Cancer 21-st Century and Beyond Expert Rev Anticancer Ther 2007; 7 (10): 1339–45.
- Burger R.A. Experience with Bevacizumab in the Management of Epithelial Ovarian Cancer. J Clin Oncol 2007; 25 (20): 2902–8.
- Shen G.H et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83: 196–203.
- Katsumata N et al. Dose - dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open - label, randomized controlled trial. Lancet 2009.
- Cook K.M, Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. A Cancer J Clin 2010; 60 (4): 222–43.
- Burger R.A, Brady M.F, Bookman M.A et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–83.
- Perren T.J, Swart A.M, Pfisterer J et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med 2011; 365: 2484–96.
- Gonzalez-Martin et al. Safety of front - line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA. ASCO 2012 (abstr. 5017).
- Pujade-Lauraine et al. AURELIA: A randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum - resistant recurrent ovarian cancer. J Clin Oncol 2012; 30 (Suppl; abstr. LBA5002).
- Carol Aghajanian et al. An updated safety analysis of OCEANS, a randomized, double - blind, phase III trial of gemcitabine and carboplatin with bevacizumab or placebo followed by BV or PL to disease progression in patients with platinum - sensitive recurrent ovarian cancer. J Clin Oncol 2012; 30 (Suppl; abstr. 5054).
